We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 40

Barbados launches biotech initiative designed to shorten R&D process
  • Shook Hardy & Bacon LLP
  • Barbados
  • December 16 2010

The Barbados government has recently launched two initiatives to attract biotech companies to the island nation


Financial group analyzes M&A deals in biotech and medical device industries
  • Shook Hardy & Bacon LLP
  • USA
  • June 16 2011

According to an SVP Financial Group report, contrary to conventional wisdom, biotech exits occur faster than device exits and have lower, but solid, multiples on invested capital


Dietary Supplement & Cosmetics Legal Bulletin: November 2016
  • Shook Hardy & Bacon LLP
  • Canada, USA
  • November 30 2016

The Federal Trade Commission (FTC) has secured orders against 29 defendants whom it claims deceptively marketed and billed consumers for skin care


Molecular diagnostics company nets $27.7 million from common stock offering
  • Shook Hardy & Bacon LLP
  • USA
  • September 26 2013

Illinois-based Nanosphere, Inc. has reportedly closed a public offering of more than 17 million shares of common stock at $1.75 per share, including


Biotech investments rise in Q4 2012, but remain off for the year
  • Shook Hardy & Bacon LLP
  • USA
  • January 24 2013

Pricewatershouse Coopers LLP has released its fourth quarter (Q4) and final 2012 venture capital investment reports and notes that "Biotechnology


Synageva announces $25 million for rare disease product development
  • Shook Hardy & Bacon LLP
  • USA
  • April 7 2011

Synageva BioPharma Corp. has announced an additional $25 million in private equity financing to support therapeutic product development


Biotech companies struggling in public markets
  • Shook Hardy & Bacon LLP
  • USA
  • April 7 2011

While five venture-capital backed biotech companies have reportedly gone public in 2011, each has been forced to lower its offering price even before the initial public offering took place due to weakened demand


Indian officials to scrutinize pharmaceutical M&As
  • Shook Hardy & Bacon LLP
  • India
  • October 20 2011

Indian ministry officials have apparently decided that foreign companies may continue to invest in new pharmaceutical industry projects but that foreign proposals for mergers and acquisitions in this sector will have to undergo enhanced scrutiny


Pharma merger activity attributed to “patent cliff”
  • Shook Hardy & Bacon LLP
  • USA
  • November 18 2010

Noting that many of the pharmaceutical industry's best-selling products will soon lose their patent protection, industry analysts have reportedly suggested that the potential loss of nearly one-third of industry revenues in the near term could account for recent merger activity among the world's largest pharmaceutical companies


Company secures $10 million in venture capital financing to improve DNA sequencing technology
  • Shook Hardy & Bacon LLP
  • USA
  • September 22 2011

NABsys, Inc., a Rhode Island-based developer of electronic systems used for sequencing and analyzing single-molecule DNA, has reportedly raised $10 million in new venture capital funding, closing a Series C preferred stock financing round